Pharmacokinetic study of tacrolimus in cystic fibrosis and non-cystic fibrosis lung transplant patients and design of bayesian estimators using limited sampling strategies

Clinical Pharmacokinetics

Volumn 44, Issue 12, 2005, Pages 1317-1328

  Saint Marcoux, Franck ^a   Knoop, Christiane ^b   Debord, Jean ^a   Thiry, Philippe ^b   Rousseau, Annick ^a,c   Estenne, Marc ^b   Marquet, Pierre ^a  

^a LIMOGES UNIVERSITY HOSPITAL   (France)

^b ERASME HOSPITAL   (Belgium)

^c UNIVERSITY OF LIMOGES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ADULT; AREA UNDER THE CURVE; ARTICLE; BAYES THEOREM; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION COEFFICIENT; CYSTIC FIBROSIS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG EXPOSURE; DRUG MEGADOSE; DRUG MONITORING; FEMALE; HUMAN; LUNG TRANSPLANTATION; MALE; PRIORITY JOURNAL; RECIPIENT; RETROSPECTIVE STUDY; SAMPLING; STATISTICAL MODEL;

ADULT; AREA UNDER CURVE; BAYES THEOREM; CYSTIC FIBROSIS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG TRANSPLANTATION; MODELS, BIOLOGICAL; TACROLIMUS;

EID: 29244478291     PISSN: 03125963     EISSN: 03125963     Source Type: Journal    
DOI: 10.2165/00003088-200544120-00010     Document Type: Article

References (32)

1. Peters DH, Fitton A, Plosker GL, et al. Tacrolimus: a review of its pharmacology, and therapeutic potential in hepatic and renal transplantation. Drugs 1993; 46: 746-94
2. Scott LJ, McKeage K, Keam SJ, et al. Tacrolimus: a further update of its use in the management of organ transplantation. Drugs 2003; 63: 1247-97
3. Hertz MI, Taylor DO, Trulock EP, et al. The registry of the International Society for Heart and Lung Transplantation: 19th official report, 2002. J Heart Lung Transplant 2002; 21: 950-70
4. McCurry KR, Zaldonis DB, Keenan RJ, et al. Long term follow-up of a prospective randomised trial of tacrolimus versus cyclosporine in human lung transplantation [abstract]. Am J Transplant 2002; 2 Suppl. 3: S159
5. Zuckermann A, Reichenspurner H, Jacksch P, et al. Long term follow-up of a prospective randomized trial comparing tacrolimus versus cyclosporine in combination with MMF after lung transplantation. J Heart Lung Transplant 2003; 22 Suppl. 1: S76-7
6. Treede H, Reichenspurner H, Meiser B, et al. Influence of four different immunosuppressive protocols on acute and chronic rejection (BOS) after lung transplantation: experience in 120 patients [abstract]. J Heart Lung Transplant 2001; 20: 176
7. Treede H, Klepetko W, Reichenspurner H, et al. Tacrolimus versus cyclosporine after lung transplantation: a prospective randomized two-center trial comparing two different immunosuppressive protocols. J Heart Lung Transplant 2001; 20: 511-7
8. Roman A, Bravo C, Monforte V, et al. Preliminary results of rescue therapy with tacrolimus and mycophenolate mofetil in lung transplanted patients with bronchiolitis obliterans. Transplant Proc 2002; 34: 146-7
9. Vitulo P, Oggionni T, Cascina A, et al. Efficacy of tacrolimus rescue therapy in refractory acute rejection after lung transplantation. J Heart Lung Transplant 2002; 21: 435-9
10. Fieguth H, Krueger S, Wiedenmann D, et al. Tacrolimus for treatment of bronchiolitis obliterans syndrome after unilateral and bilateral lung transplantation. Transplant Proc 2002; 34: 1884-9
11. Verderlen GM, Buyse B, Delcroix M, et al. Changing cyclosporine to tacrolimus after lung transplantation: reasons and outcome [abstract]. Eur Respir J 2000; 16 Suppl. 1: S510
12. Klepetko W, Sarahrudi K, Corris P, et al. Efficacy of conversion from cyclosporin A to tacrolimus in lung transplantation [abstract]. Am J Transplant 2002; 2 Suppl. 3: S159
13. Kahan BD, Keown P, Levy GA, et al. Therapeutic drug monitoring of immunosupressant drugs in clinical practice. Clin Ther 2002; 24: 330-50
14. Fukatsu S, Yano I, Igarashi T, et al. Population pharmacokinetics of tacrolimus in adult recipients receiving living-donor liver transplantation. Eur J Clin Pharmacol 2001; 57: 479-84
15. Staatz CE, Willis C, Taylor PJ, et al. Toward better outcomes with tacrolimus therapy: population pharmacokinetics and individualized dosage prediction in adult liver transplantation. Liver Transpl 2003; 9: 130-7
16. Staatz CE, Willis C, Taylor PJ, et al. Population pharmacokinetics of tacrolimus in adult kidney transplant recipients. Clin Pharmacol Ther 2002; 70: 660-9
17. Zahir H. MacLachlan AJ, Nelson A, et al. Population pharmacokinetic estimation of tacrolimus apparent clearance in adult liver transplant recipients. Ther Drug Monit 2005; 27 (4): 422-30
18. Antignac M, Hulot JS, Boleslawski E, et al. Population pharmacokinetics of tacrolimus in full liver transplant patients: modelling of the post-operative clearance. Eur J Clin Pharmacol 2005; 61 (5-6): 409-16
19. Macchi-Andanson M, Charpiat B, Jelliffe RW, et al. Failure of traditional trough levels to predict tacrolimus concentrations. Ther Drug Monit 2001; 23: 129-33
20. Fukudo M, Yano I, Fukatsu S, et al. Forecasting of blood concentrations based on the Bayesian method in adult patients receiving living-donor liver transplantation. Clin Pharmacokinet 2003; 42: 1161-78
21. Willis C, Staatz CE, Tett SE. Bayesian forecasting and prediction of tacrolimus concentrations in pediatric and adult renal transplant patients. Ther Drug Monit 2003; 25: 158-66
22. Debord J, Risco E, Harel M, et al. Application of a gamma model of absorption to oral cyclosporin. Clin Pharmacokinet 2001; 40: 375-82
23. Léger F, Debord J, Le Meur Y, et al. Maximum a posteriori bayesian estimation of oral cyclosporine pharmacokinetics in stable renal transplant patients. Clin Pharmacokinet 2002; 41: 71-80
24. Monchaud C, Léger F, Rousseau A, et al. Bayesian forecasting of oral cyclosporine in cardiac transplant recipients. Eur J Clin Pharmacol 2003; 58: 813-20
25. Rousseau A, Monchaud C, Debord J, et al. Bayesian forecasting of oral cyclosporin in stable lung transplant recipients with and without cystic fibrosis. Ther Drug Monit 2003; 25: 28-35
26. Akaike H. A new look at the statistical model identification. IEEE Trans Automat Control 1974; 19: 716-23
27. D'argenio DZ. Optimal sampling times for pharmacokinetics experiments. J Pharmacokinet Biopharm 1981; 9: 739-5
28. Staatz CE, Tett SE. Clinical phamacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet 2004; 43 (10): 623-53
29. Saeki T, Ueda K, Tanigawara Y, et al. Human P-glycoprotein transports cyclosporin A and FK506. J Biol Chem 1993; 268: 6077-80
30. Hashida T, Masuda S, Uemoto S, et al. Pharmacokinetic and prognostic significance of intestinal MDR1 expression in recipients of living-donor liver transplantation. Clin Pharmacol Ther 2001; 69 (5): 308-16
31. Susanto M, Benet LZ. Can enhanced renal clearance of antibiotics in cystic fibrosis patients be explained by P-glycoprotein transport. Pharm Res 2002; 19 (4): 457-62
32. Morton JM, Kear M, Williamson S, et al. Trough levels are inadequate for monitoring tacrolimus pharmacokinetics in lung transplantation. J Heart Lung Transplant 2002; 21: 143-4